Skip to main content

Table 2 Observed sustained virological response rates at 4 weeks (SVR4) and at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin

From: The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

Observed SVR4 SVR12
  As-treated Intent-to-treat As-treated Intent-to-treat
Country % Fraction % Fraction % Fraction % Fraction
Austria 100 14/14 100 14/14 100 13/13 93 13/14
Denmark 94 17/18 89 17/19 100 17/17 89 17/19
Spain 99 141/142 94 141/150 99 138/140 92 138/150
Sweden 100 15/15 94 15/16 100 15/15 94 15/16
Switzerland 85 23/27 82 23/28 85 22/26 85 22/26
UK 100 14/14 82 14/17 100 14/14 82 14/17
Overall 97 224/230 92 224/244 97 219/225 90 219/242